Home  |  About JAPTR |  Editorial board  |  Search |  Ahead of print  |  Current issue  |  Archives |  Submit article  |  Instructions  |  Subscribe  |  Advertise  |  Contacts  |Login 
Users Online: 245   Home Print this page Email this page Small font sizeDefault font sizeIncrease font size
     

 Table of Contents  
EDITORIAL
Year : 2017  |  Volume : 8  |  Issue : 2  |  Page : 45  

Current trends in bone tissue regeneration


Editor, Journal of Advanced Pharmaceutical Technology and Research (JAPTR), Editor-in-Chief, SPER Times, Secretary, Society of Pharmaceutical Education and Research, 22-C, Jawahar Colony, Gwalior - 474 001, Madhya Pradesh, India

Date of Web Publication11-Apr-2017

Correspondence Address:
Upendra Nagaich
Editor, Journal of Advanced Pharmaceutical Technology and Research (JAPTR), Editor-in-Chief, SPER Times, Secretary, Society of Pharmaceutical Education and Research, 22-C, Jawahar Colony, Gwalior - 474 001, Madhya Pradesh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/japtr.JAPTR_10_17

Rights and Permissions

How to cite this article:
Nagaich U. Current trends in bone tissue regeneration. J Adv Pharm Technol Res 2017;8:45

How to cite this URL:
Nagaich U. Current trends in bone tissue regeneration. J Adv Pharm Technol Res [serial online] 2017 [cited 2017 Aug 20];8:45. Available from: http://www.japtr.org/text.asp?2017/8/2/45/204336



Over the past two decades, bone tissue engineering has been the issue of considerable research in the era of regenerative medicine. The reason might be attributed to the many skeletal problems stay undertreated, which leads to rigorous optimization and improvement of regeneration therapies. The current trends include the technical advances in orthopedic implants and surgical techniques for bone regeneration. In the plethora of treatments available for bone reconstruction, gene therapy has also gain significant attention. For bone regeneration, tissue engineering strategies comprise protein, gene, and cell delivery to the defective bone site. Furthermore, the bone repair process was significantly enhanced by biomimetic scaffolds and scaffolds loaded with bone anabolic agents. Directed and controlled gene therapy at defective bone region has the major prospective of augmenting bone defect healing through local delivery of osteogenic genes to lesion in bones, thus circuitously declining systemic toxicity and necessity to use elevated dosages of therapeutic proteins. Gene-activated matrices (GAMs) have shown considerable outcomes with bone regeneration. In GAM technology, cytokines and growth factors could be delivered as plasmid genes, not recombinant proteins which lead to in situ osteogenic protein production, thus inducing osteogenesis and bone repair. On the contrary, the critical factor in gene therapy includes the synthesis of clinically beneficial number of proteins around the defective osseous site in a sustained manner. Thus, major concern is the development of reliable gene delivery methods. Several practical factors also need to be considered, namely, age, gender, health of patients, and nature of the disease process for progressing a clinically applicable gene therapy for bone regeneration. Overall, a common platform for clinical experience, biological principles' facts, demand, and commercial application is necessary for the technology development.






 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article

 Article Access Statistics
    Viewed237    
    Printed10    
    Emailed0    
    PDF Downloaded113    
    Comments [Add]    

Recommend this journal